CBOE Holdings Inc.

05/15/2019 | Press release | Distributed by Public on 05/15/2019 05:09

Teleflex Reports Will Highlight Arrow, MANTA At European Association for Percutaneous Cardiovascular Interventions Course

Cboe - Market News Story

Teleflex Reports Will Highlight Arrow, MANTA At European Association for Percutaneous Cardiovascular Interventions Course

Benzinga Newsdesk 5/15/2019 5:32:53 AM

Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies for critical care, urology and surgery, coronary and peripheral interventions, will showcase its complex PCI product portfolio, the Arrow® AC3 Optimus™ Intra-Aortic Balloon Pump (IABP) and the newly acquired MANTA™ Vascular Closure Device at the EuroPCR being held in Paris, France on May 21 - 24, 2019.

Teleflex offers a full line of products that give interventional cardiologists the tools they need to handle routine and complex cases, resulting in improved outcomes for patients. Cardiologists worldwide rely on the quality and proven clinical effectiveness of products, such as the GuideLiner® V3 Catheter, TrapLiner® Catheter, Turnpike® Catheter, Twin-Pass® Torque Dual Access Catheter, SuperCross® Microcatheter, and R350™ Guidewire.

At EuroPCR, Teleflex will showcase the MANTA™ Vascular Closure Device indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20F devices or sheaths (12-25F OD) in endovascular catheterization procedures. With the MANTA™ Device, clinicians and hospitals can achieve:

  • Successful large bore closure with a device that is simple to use and does not require pre-closure, saving valuable time during the most delicate interventional procedures.
  • Low complication rates for fast reliable biomechanical closure with rapid hemostasis, potentially reducing costs.1a,b
  • Reproducible results, inspiring confidence in achieving successful closure.1c

Finally, Teleflex will continue presenting the Arrow® AC3 Optimus™ IABP. This device helps a weakened heart pump blood and can deliver IABP therapy to a broad range of patients, even those not previously considered candidates for IABP therapy. Clinicians may use the pump on patients with severe arrhythmias or with heart rates as high as 200 beats per minute.2, 3 The Arrow® AC3 Optimus™ IABP with third-generation AutoPilot® Mode uses proprietary algorithms to address key clinical challenges and simplifies delivery of IABP therapy.4